STOCKS TELEGRAPH

Tag: ADMA

  • Why is the stock of ADMA Biologics Inc. (ADMA) skyrocketing in premarket?

    Why is the stock of ADMA Biologics Inc. (ADMA) skyrocketing in premarket?

    ADMA Biologics, Inc. (ADMA) a biopharmaceutical company focused on commercializing specialty plasma-derived biologics, confirmed that the U.S. Food and Drug Administration (FDA) has approved the Company’s enlarged production process, which allows fractionation and purification of plasma pool with a 4400 liter volume, to produce Intravenous Immune Globulin (“IVIG”). ADMA stock surged adjacent to the news.

    At last check in premarket trading, shares of ADMA Biologics Inc. (ADMA) were up 17.89% at $2.06. The price range of the company’s shares was between $1.82 and $1.95. The stock recorded a trading volume of 1.69 million shares, which is below the average daily trading volume published for the last 50 days of 3.16 million shares.

    About ADMA Biologics, Inc

    ADMA has presently developed three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and to prevent several infectious diseases and provide enhanced immunity. ADMA produces its immune globulin-related products in Boca Raton, Florida, at its FDA-licensed plasma fractionation and purification facility. ADMA also focuses on plasma collecting in the U.S., which provides a portion of its blood plasma to produce its products.

    The 4,400-liter IVIG plasma pool scale for BIVIGAM® lets ADMA increases the production plant’s total processing volume from 400,000 liters to an expected 600,000 liters. Allowing ADMA to manufacture BIVIGAM® at an increased capacity, maintaining the same quality as the previous manufacturing scale, while using the same machinery and labor force.

    ADMA expects this will improve gross margins due to increased production combined with economies of scale. With this approval for FDA, ADMA additionally will now be able to offer BIVIGAM® in two unique sizes, consisting of 50ml and 100ml variations.

    “The FDA approval of the 4,400-liter IVIG plasma pool production scale process is a transformative milestone for the ADMA organization and will allow the Company to produce significantly more IVIG for the U.S. market and for patients living with immune deficiencies,” said Adam Grossman, President and Chief Executive Officer of ADMA.

    ADMA Biologics is expecting its quarter-over-quarter revenue to grow throughout 2021 due to a substantial increase in production capacity. Expansion of plasma pool manufacturing has allowed the company to forecast generating more than $300M in revenue. Enhanced Gross Margins and Cost Efficiencies are expected to accelerate in 2022 and provide profitability.

    Conclusion.

    FDA approval for the Company’s enlarged manufacturing process has peaked investor interest. Total Capacity increase from 400,000 Liters up to 600,000 Liters has forecasted revenue to surge substantially, with ADMA stock rising immensely.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

  • What changed for these 30 stocks in Pre Market Session

    What changed for these 30 stocks in Pre Market Session

    Usio Inc. (USIO) stock soared 41.54% to $2.59 in the pre-market trading after declaring that it has entered into a non-binding Letter of Intent (LOI) to acquire the assets of Information Management Solutions, LLC (IMS).
    NeuroMetrix Inc. (NURO), a Medical Instruments & Supplies company, dropped about -8.03% at $2.75 in pre-market trading Wednesday.
    Cinedigm Corp. (CIDM) stock moved up 43.36 percent to $1.23 in the pre-market trading following a strategic alliance with Spherex to drive Cinedigm’s global growth.
    Recon Technology Ltd. (RCON) stock moved up 112.5 percent to $3.06 in the pre-market trading.
    Curis Inc. (NASDAQ: CRIS) shares are trading up 2.29% at $6.7 at the time of writing after revealing proposed public offering of common Stock. Company’s 52-week ranged between $0.62 to $3.59. Analysts have a consensus price target of $5.
    Gran Tierra Energy Inc. (GTE) lost over -7.04% at $0.355 in pre-market trading Wednesday December 09, 2020. The firm recently declared a financial update and the Company’s 2021 capital budget and production guidance.
    Aurora Cannabis Inc. (ACB) is down more than -0.94% at $10.5 in pre-market hours Wednesday December 09, 2020. The stock had jumped over 1.24% to $10.60 in the last trading session.
    Carnival Corporation & Plc (CCL) is up more than 2.76% at $24.22 in pre-market hours Wednesday December 09, 2020 following declaration of Cunard, a part of Carnival Corporation & plc (CCL), that it has extended its pause in operations due to the ongoing travel constraints in place across the world. The stock had jumped over 1.59% to $23.57 in the last trading session.
    Before the trading started on December 09, 2020, Occidental Petroleum Corporation (OXY) is up 2.56% to reach $19.62 after reporting upsize of previously announced cash tender offers and consent solicitations for certain of its senior notes. It has been trading in a 52-week range of $8.52 to $47.58.
    Virgin Galactic Holdings Inc. (SPCE) stock soared 2.55% to $34.24 in the pre-market trading. The most recent rating by Goldman, on October 23, 2020, is a Neutral.
    Eastman Kodak Company (NYSE: KODK) shares are trading down -4.04% at $10.7 at the time of writing after getting clean chit from U.S government regarding a government loan. Company’s 52-week ranged between $1.50 to $60.00.
    Moderna Inc. (MRNA) grew over 3.38% at $175.6 in pre-market trading today after declaring that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
    Riot Blockchain Inc. (RIOT), a Software – Application company, dropped about -5.78% at $9.3 in pre-market trading Wednesday.
    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, rose about 1.95% at $28.7 in pre-market trading Wednesday after announcing partnership with AtmosAir Solutions.
    XPeng Inc. (XPEV) stock moved down -3.72 percent to $46.88 in the pre-market trading following the pricing of follow-on public offering of American depositary shares.
    Cinemark Holdings Inc. (CNK) stock soared 2.26% to $15.36 in the pre-market trading. The most recent rating by Loop Capital, on November 19, 2020, is a Hold.
    Before the trading started on December 09, 2020, Tonix Pharmaceuticals Holding Corp. (TNXP) is up 0.15% to reach $0.65 after declaring results of positive phase 3 RELIEF study for TNX-102 SL 5.6 mg in Fibromyalgia. It has been trading in a 52-week range of $0.39 to $2.46.
    CBAK Energy Technology Inc. (NASDAQ: CBAT) shares are trading up 3.3% at $5.95 at the time of writing following the publication of securities purchase agreement with certain institutional investors for a registered direct placement of approximately $49.2 million of common stock at a price of $5.18 per share. Company’s 52-week ranged between $0.36 to $11.40.
    Jaguar Health Inc. (NASDAQ: JAGX) shares are trading down -4.84% at $0.3798 at the time of writing. Company’s 52-week ranged between $0.19 to $1.08. Analysts have a consensus price target of $2.
    United Airlines Holdings Inc. (UAL) grew over 1.88% at $49.96 in pre-market trading today after launching virtual, on demand customer service at the airport.
    GameStop Corp. (GME) is down more than -17.59% at $13.96 in pre-market hours Wednesday December 09, 2020 after releasing results for the third quarter ended October 31, 2020. The stock had jumped over 3.61% to $16.94 in the last trading session.
    Before the trading started on December 09, 2020, ADMA Biologics Inc. (ADMA) is up 4.31% to reach $2.18. It has been trading in a 52-week range of $1.45 to $4.65.
    Before the trading started on December 09, 2020, HEXO Corp. (HEXO) is down -2.91% to reach $1.0. The firm recently reported downward revision to its proposed share consolidation ratio. It has been trading in a 52-week range of $0.35 to $2.30.
    United Microelectronics Corporation (UMC) is up more than 1.37% at $8.88 in pre-market hours Wednesday December 09, 2020 afterreporting unaudited net sales for the month of November 2020. The stock had dropped over -3.10% to $8.76 in the last trading session.
    Apache Corporation (NASDAQ: APA) shares are trading up 1.08% at $14.92 at the time of writing following the board of directors of Apache Corporation (APA) has declared a regular cash dividend on the company’s common shares. Company’s 52-week ranged between $3.80 to $33.77. Analysts have a consensus price target of $16.
    Phunware Inc. (PHUN) stock moved down -3.28 percent to $0.81 in the pre-market trading after revealing its receipt of the Privacy Shield certification.
    Sorrento Therapeutics Inc. (SRNE) stock soared 9.62% to $8.66 in the pre-market trading after declaring that it has received CLIA Licensure from the State of California that permits testing of clinical samples. The most recent rating by H.C. Wainwright, on July 31, 2020, is a Buy.
    Sesen Bio Inc. (SESN) gained over 5.42% at $1.75 in pre-market trading Wednesday December 09, 2020 following the announcement of commercial manufacturing and global supply partnership with Qilu Pharmaceutical.
    Before the trading started on December 09, 2020, Futu Holdings Limited (FUTU) is up 2.27% to reach $44.61 after reporting that a leading global investment firm has agreed to purchase approximately 50,000,000 Class A ordinary shares of the Company in the form of prepaid warrants for an aggregate purchase price of approximately US$260,000,000. It has been trading in a 52-week range of $8.16 to $51.10.
    Westwater Resources Inc. (WWR) stock soared 3.87% to $5.63 in the pre-market trading. The company recently provided an update on progress at its pilot plant operations at Dorfner Anzaplan’s facilities near Amberg, Germany, as well as at facilities in Frankfort, Germany, Chicago, Illinois, and Buffalo, New York.

  • ADMA Biologics Inc [NASDAQ:ADMA] Set for More Gains as FDA Approves Plasma COVID-19 Treatment

    ADMA Biologics Inc [NASDAQ:ADMA] Set for More Gains as FDA Approves Plasma COVID-19 Treatment

    ADMA Biologics Inc [NASDAQ: ADMA] is a top performer this afternoon. Like other companies that deal in plasma biologics, this stock has benefitted from the FDA’s approval of the use of blood plasma in the treatment of COVID-19.

    Yesterday, the FDA released a statement stating that it was issuing an Emergency Use Authorization for the use of plasma in the treatment of COVID-19 on the basis of prevailing scientific evidence showing that it works. Commenting on the move, the U.S Health and Human Services Secretary Alex Azar stated that the decision by the FDA was a huge milestone in the Trump administration’s efforts to fight the coronavirus. On his part, FDA Commissioner Stephen M.

    Hahn stated that the body was fully committed to releasing safe and helpful treatments for COVID-19. He added that it is on this basis that the FDA was authorizing the use of convalescent plasma after it had shown promising results in the fight against COVID-19. On the basis of prevailing evidence, the FDA had established that the use of convalescent plasma was effective in lowering the severe effects of the disease and in shortening the time that one spent in the hospital. It also established that the potential effects of the treatments were much lower than the possible benefits that come with using it.

    Why the gains?

    The company’s rally is in line with the market-wide rally touching on stocks that deal in plasma biologics. That’s because these companies already have the infrastructure for plasma-related treatments.  As such, investors expect that they will channel a sizeable portion of their resources towards the fight against COVID-19, a factor that could see these companies recorded revenue growth going into the future.

    ADMA Biologics has the infrastructure for use in developing plasma treatments for COVID-19. The company is specialized in immunoglobulins and is known for its capabilities in developing plasma-based treatments for infectious diseases. Since COVID-19 is an infectious disease, it falls right within the speciality of the company. Over the years, the company has developed a range of plasma-based therapeutics including for the treatment of pneumonia.

    The company also has the infrastructure for the collection of blood plasma, which places it right in the centre for the collection of blood plasma of recovered COVID-19 patients. On this basis, it stands to keep gaining as investors expect it to be at the centre of the fight against COVID-19 in the U.S.

    About ADMA Biologics Inc

    ADMA Biologics Inc is a biopharma company. It is based in Ramsey, New Jersey.

  • High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment

    High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment

    The markets are up this morning driven by news that the U.S had approved a COVID-19 treatment. Yesterday, the U. S FDA issued an emergency use authorization for the use of blood plasma from people who had recovered from COVID-19 as a treatment.

    In a statement, the FDA said that on the basis of available scientific evidence, the blood plasma of people who had recovered from COVID-19 had benefits that outweighed any potential risks. The statement further stated that the Emergency Use Authorization gave the green light for the distribution of the product in the U.S for use by healthcare providers to treat people hospitalized with COVID-19.

    Commenting on the development, President Trump has stated that the treatment had so far cut mortality rates by 35%, quoting a study by the Mayo Clinic. Over the weekend, it was also reported that the President was considering fast-tracking a vaccine that was being developed by Oxford University in the U.K.

    All these news have led to a surge in optimism across the financial markets, and major U.S indices are strong pre-market. In this environment of high optimism, plasma-related biopharma companies are rallying. Some of the biggest gainers this morning are as below:

    ADMA Biologics Inc [NASDAQ: ADMA]

    ADMA Biologics is flying high this morning after the FDA approved the use of recovered COVID-19 patients’ plasma as a treatment.

    At the time of writing, the stock was up by 70% and gaining. The company is specialized in making plasma biologics for the treatment of a wide array of immune deficiencies and infectious diseases. With the use of plasma approved, investors are optimistic that with its infrastructure in plasma-based treatments, this company stands to benefit significantly in the foreseeable future.

    ThermoGenesis Holdings Inc [NASDAQ: THMO]

    ThermoGenesis Holdings Inc is another plasma-treatment biotech company that is rallying this morning.  The company has the infrastructure for it, and investors are optimistic that it stands to benefit from the approved treatment.

    The company operates in two segments and one of them is involved in automated cell separation of progenitor and stem cells taken from umbilical cords blood. It is also involved in the preservation of such blood for clinical applications.

    Liminal Biosciences Inc [NASDAQ: LMNL]

    This is another top performer this morning and is up by over 60% in pre-market trading. The company operates in two segments and one of them is called Plasma Derived Therapeutics. This segment of the company has a plasma protein purification system that is used in the extraction of protein therapeutics from plasma.